The peptide and gut-barrier axis: enteric coatings, KPV, larazotide, and what oral peptides actually do in the small intestine

The stomach as a protease environment

The fasted-state human stomach has a pH between 1.5 and 3.5 and an active complement of pepsin, the dominant gastric protease. Most therapeutic peptides do not pass through this environment intact. Pepsin cleaves preferentially at hydrophobic and aromatic residues, and the acidic pH alone denatures secondary and tertiary structure that depends on disulfide bonds or salt bridges. The published gastric proteolysis literature catalogs the half-lives of common peptide drugs in simulated gastric fluid; most fall below 30 minutes .

GLP-1 itself is a textbook example. Native GLP-1 has a circulating half-life of 1 to 2 minutes because of dipeptidyl peptidase 4 cleavage at the N-terminus. Oral semaglutide (Rybelsus) is the only commercially available oral GLP-1 receptor agonist, and it relies on a permeation enhancer (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, SNAC) that creates a transient local pH bubble in the stomach to allow some semaglutide molecules to cross the gastric epithelium intact . Bioavailability is still around 1 percent, which is high enough to support clinical dosing only because the parent molecule is otherwise pharmacologically potent.

What enteric coatings actually do, and why they help only some peptides

An enteric coating is a polymer shell (commonly methacrylic acid copolymers like Eudragit, or hydroxypropyl methylcellulose phthalate) that resists dissolution at acidic pH and dissolves at the higher pH of the proximal small intestine, typically pH 5.5 to 6.5. The shell protects the payload through the stomach and releases it in the duodenum or jejunum.

The catch is that the duodenum and jejunum still contain pancreatic proteases (trypsin, chymotrypsin, elastase, carboxypeptidases) released from the pancreas in response to a meal. These proteases work at neutral or slightly alkaline pH and cleave at different bonds than pepsin. A peptide that survives the stomach because of an enteric coating can still degrade in the small intestine within minutes if it carries trypsin or chymotrypsin cleavage motifs.

• Enteric coating is necessary but not sufficient for oral bioavailability of most peptides.
• Peptides cyclized through head-to-tail amide or disulfide bonds are more resistant to small-intestinal proteases than linear sequences.
• Modifications like N-methylation of backbone amides, D-amino acid substitution, and PEGylation extend gut residence time but can reduce receptor affinity.
• Permeation enhancers (SNAC, caprate, cell-penetrating peptide tags) are the second tool in the kit, but they have their own pharmacokinetic and tolerability profiles.

Tight junctions, zonulin, and the larazotide story

The intestinal epithelium is a single-cell-thick barrier sealed at the apical side by tight junctions: protein complexes of claudins, occludins, and zonula occludens proteins that regulate paracellular permeability. Most peptides cross the gut barrier paracellularly only when those tight junctions transiently open, which is why the regulatory biology of the tight junction matters for oral peptide delivery.

Zonulin is a protein that signals tight-junction loosening through an EGF-receptor-related pathway. Larazotide acetate (AT-1001) is a synthetic octapeptide that competitively blocks zonulin signaling, reducing tight-junction opening. It has been studied in celiac disease as an adjunct to a gluten-free diet and reached late-stage human trials before the program was paused; ClinicalTrials.gov lists the registered protocols . Larazotide is therefore an interesting reverse case: rather than crossing the gut barrier, it acts on the gut barrier itself, and the trial endpoints measure intestinal permeability and symptom burden rather than systemic drug concentration.

KPV and the localized anti-inflammatory pattern

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (lysine-proline-valine). The published preclinical literature documents anti-inflammatory effects in colitis models when KPV is administered orally or intracolonically; effect sizes are modest but reproducible across labs . The proposed mechanism is binding to melanocortin receptors expressed on intestinal epithelial cells and leukocytes, with downregulation of NF-kB signaling.

KPV has not completed a phase 3 human trial in inflammatory bowel disease. There is no FDA-approved KPV product. The combination of small molecular size (three residues), absence of canonical protease cleavage sites in the linear sequence, and apparent local activity at the gut wall has made it a recurring research-peptide candidate, but the absence of late-stage human evidence is the critical caveat. The published primate and rodent data should not be read as a human efficacy claim.

BPC-157 and the systemic question for oral peptides

BPC-157 is a 15-residue peptide reported in human gastric juice. The community discussion of BPC-157 frequently cites oral administration in rodent studies as evidence that the molecule is orally bioavailable in humans. The leap is not warranted by the published data. Rodent gastrointestinal physiology differs from human physiology in pH, transit time, microbial composition, and protease activity. A peptide that survives a rat's small intestine may not survive the human equivalent, and vice versa.

There is no published human pharmacokinetic study of orally administered BPC-157. Claims of systemic activity from oral dosing rest on extrapolation from rodent data plus user-reported outcomes . The honest framing is that BPC-157 may exert local effects in the gut wall through a mechanism similar to KPV, but systemic post-oral activity is unverified.

What this means for readers and prescribers

• Oral peptide claims should be evaluated against three barriers: gastric proteolysis, small-intestinal proteolysis, and paracellular or transcellular crossing of the epithelium. Each barrier needs a credible answer.
• Enteric coating addresses the first barrier only. It does not address pancreatic proteases or epithelial crossing.
• Permeation enhancers (SNAC) are the only validated approach to reach systemic circulation in published label-grade products. Bioavailability remains low (~1 percent for oral semaglutide).
• Localized anti-inflammatory pathways (KPV, larazotide) do not require systemic absorption to act. Trial endpoints for these compounds reasonably measure local pharmacodynamics, not plasma drug concentration.
• Animal data, particularly rodent studies, predict human oral bioavailability poorly for peptide therapeutics. Human PK studies are the only reliable basis for oral dosing claims.